Twist Bioscience Corporation (NASDAQ: TWST) is a healthcare company, listed on the NASDAQ. Alpha Stocks Insight has published 3 articles on TWST since May 4, 2026, most recently "Twist Bioscience (NASDAQ: TWST) Posts Record $118.4M Q3 Revenue, Raises Full-Year Guidance" on Monday, August 3, 2026. Coverage to date spans Earnings Report and Health Care, tracking TWST's earnings, analyst activity, and material corporate events. New coverage is added each trading day.
Price
$125.52
Today
-1.98%
Mkt Cap
$8.3B
52W High
$155.44
52W Low
$23.30
Data via Finnhub · refreshes hourly · not financial advice
Record Q3 revenue of $118.4M grew 23% YoY, but SG&A jumped 27.3% and net loss widened to $35.1M , here's what that means for TWST.
Canaccord Genuity sets a $90 price target on TWST, implying double-digit upside from current levels as analyst Kyle Mikson opens coverage with a Buy rating.
Stock plummets 7% after Q2 revenue beat offset by widening operating losses and negative per-share earnings.
Important Legal Disclaimer
This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.
Affiliate disclosure: This site may contain affiliate links to brokerage platforms. If you open an account through one of our links, we may earn a commission at no additional cost to you. Affiliate relationships do not influence our editorial content or stock coverage decisions.
Important Legal Disclaimer: This is for informational purposes only and is not financial, investment, or tax advice. Past performance is no guarantee of future results. We are not licensed advisors. For Swiss residents: This does not constitute a public offer under FINSA. For EU residents: Not MiFID II compliant advice. For US residents: Not SEC-registered advice. Always consult a qualified professional. Investing involves risk of loss.